Cargando…
Long-term use of adalimumab in the treatment of rheumatic diseases
Adalimumab, a fully humanized monoclonal antibody against tumor necrosis factor-alpha (TNFα), has been evaluated in various randomized placebo-controlled trials in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and juvenile idiopathic arthritis. In the short time frame of these tr...
Autores principales: | Papagoras, Charalampos, Voulgari, Paraskevi V, Drosos, Alexandros A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074727/ https://www.ncbi.nlm.nih.gov/pubmed/27789981 |
Ejemplares similares
-
Comment on the Article “Adalimumab-Induced Lupus Nephritis: Case Report and Review of the Literature”
por: Drosos, Alexandros A., et al.
Publicado: (2023) -
Anti-Rheumatic Drugs for the Fight Against the Novel Coronavirus Infection (SARSCoV-2): What is the Evidence?
por: Pelechas, Eleftherios, et al.
Publicado: (2020) -
Anti-Rheumatic Drugs May Ameliorate the Clinical Course and Outcome of COVID-19 In Rheumatoid Arthritis Patients
por: Pelechas, Eleftherios, et al.
Publicado: (2022) -
Periocular xanthogranuloma: A forgotten entity?
por: Papagoras, Charalampos, et al.
Publicado: (2010) -
Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience
por: Migkos, Michalis P., et al.
Publicado: (2021)